Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Tulln An Der Donau – page 13

881 clinical trials in Tulln An Der Donau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tulln An Der Donau at a glance
881
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

881 trials in Tulln An Der Donau

Open in trial search

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:Astrazeneca AB

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

A study testing venetoclax for treating acute graft-versus-host disease in patients who received a stem cell transplant from a donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Medical University Of Vienna

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:BeOne Medicines AG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Tulln An Der Donau

What the registry says about research in the country

01 Neurological Disorders

Research focusing on Multiple System Atrophy and its associated conditions, particularly investigating new therapeutic approaches for managing neurogenic orthostatic hypotension. Studies aim to evaluate novel treatments for improving patient symptoms and quality of life.

  • Orthostatic Hypotension Management
  • Autonomic Nervous System Disorders
  • Symptomatic Treatment Evaluation

Current trials are examining long-term effectiveness and durability of new therapeutic interventions.

02 Neuropathic Pain Studies

Comprehensive research into various forms of chronic neuropathic pain, including diabetic polyneuropathy and post-operative peripheral neuropathy. Studies are evaluating new therapeutic options for patients with treatment-resistant conditions.

  • Diabetic Polyneuropathy
  • Traumatic Neuropathy
  • Central Neuropathy

Investigations focus on add-on treatments to enhance current pain management protocols.

03 Chronic Pain Management

Innovative research targeting chronic back pain and various pain conditions, evaluating new therapeutic approaches for improved patient outcomes. Studies are designed to assess both efficacy and tolerability of novel treatment options.

  • Back Pain Treatment
  • Pain Management Protocols
  • Treatment Tolerability Assessment

Current research emphasizes developing comprehensive pain management solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.